# Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia

> **NCT05237960** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Arizona** · enrollment: 34 (actual)

## Conditions studied

- Erythroplakia
- Oral Leukoplakia

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Extended Release Metformin Hydrochloride
- **DRUG:** Placebo Administration

## Key facts

- **NCT ID:** NCT05237960
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-12
- **Primary completion:** 2025-11-07
- **Final completion:** 2026-12
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05237960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05237960, "Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05237960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*